HMP Global November 18, 2025
Key Clinical Summary
The Enhancing Oncology Model (EOM) Performance Period 1 (July-December 2023) evaluation found reduced total episode payments for 6-month oncology episodes, driven chiefly by lower Part B systemic therapy costs.
Despite the payment reduction, after accounting for incentive and monthly enhanced oncology services (MEOS) payments, the model likely produced a net loss to Medicare in its first 6 months.
Practices joining EOM tended to have prior value-based oncology experience (most had participated in the legacy Oncology Care Model (OCM), were community-based, located in the South, and had higher baseline episode volumes than non-participating practices.
The Centers for Medicare & Medicaid Services (CMS) and independent evaluators have released the first annual evaluation report of the Enhancing Oncology Model. The...
Today's Sponsors
Today's Sponsor